Furthermore, in those few patients who relapsed long after alemtuzumab treatment, striking alterations in ILC numbers and proportions were seen as MS became active, suggesting that ILC dysregulation may be one of the first indications of the resumption of autoimmunity. The gene discussed is CCL27; the disease is myeloid sarcoma.